تقرير
Brigatinib in
| العنوان: | Brigatinib in |
|---|---|
| المؤلفون: | Plotkin, Scott R, Yohay, Kaleb H, Nghiemphu, Phioanh L, Dinh, Christine T, Babovic-Vuksanovic, Dusica, Merker, Vanessa L, Bakker, Annette, Fell, Geoffrey, Trippa, Lorenzo, Blakeley, Jaishri O |
| المصدر: | N Engl J Med ; ISSN:1533-4406 ; Volume:390 ; Issue:24 |
| بيانات النشر: | New England Journal of Medicine |
| سنة النشر: | 2024 |
| المجموعة: | PubMed Central (PMC) |
| الوصف: | NF2-related schwannomatosis (NF2-SWN, formerly called neurofibromatosis type 2) is a tumor predisposition syndrome that is manifested by multiple vestibular schwannomas, nonvestibular schwannomas, meningiomas, and ependymomas. The condition is relentlessly progressive with no approved therapies. On the basis of preclinical activity of brigatinib (an inhibitor of multiple tyrosine kinases) in NF2-driven nonvestibular schwannoma and meningioma, data were needed on the use of brigatinib in patients with multiple types of progressive NF2-SWN tumors. |
| نوع الوثيقة: | report article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://doi.org/10.1056/NEJMoa2400985Test; https://pubmed.ncbi.nlm.nih.gov/38904277Test |
| DOI: | 10.1056/NEJMoa2400985 |
| الإتاحة: | https://doi.org/10.1056/NEJMoa2400985Test https://pubmed.ncbi.nlm.nih.gov/38904277Test |
| حقوق: | Copyright © 2024 Massachusetts Medical Society. |
| رقم الانضمام: | edsbas.86BD3515 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1056/NEJMoa2400985 |
|---|